Researchers harness metabolism to reverse aggressiveness in leukemia

May 17, 2017 by Alan Flurry, University of Georgia
Takahiro Ito is an assistant professor in UGA's Franklin College of Arts and Sciences department of biochemistry and molecular biology. Credit: University of Georgia

University of Georgia researchers, with colleagues from the University of Tokyo, have identified a new drug target for the two most common types of myeloid leukemia, including a way to turn back the most aggressive form of the disease. They published their findings today in the journal Nature.

By blocking a protein called BCAT1, the researchers were able to stop cancer in mice and human samples from patients.

The BCAT1 protein activates the metabolism of a group of amino acids known as branched-chain amino acids, or BCAAs, that are essential building blocks of proteins in all and thus necessary for aggressive to grow. The same enzymes are also responsible for the development of brain and lung tumors.

Earlier research indicated that BCAT functions to break down the BCAAs in most healthy tissues. The new paper shows for the first time that, rather than to break them down, leukemia cells use the BCAT1 pathway to produce BCAAs. By blocking the protein, researchers can reverse the disease's aggressiveness.

"We wanted to understand what is driving aggressiveness in acute leukemia, and then examine whether targeting such a pathway would reverse the disease back to the treatable ," said Takahiro Ito, senior author on the paper and assistant professor in the Franklin College of Arts and Sciences department of biochemistry and molecular biology.

Chronic myeloid leukemia is a kind of blood cancer with three major clinical phases: a chronic phase, an accelerated phase and an acute or blast crisis phase. Chronic leukemia usually responds well to treatments with TKI drugs. But if the cancer is left untreated or resistance develops, mutations will eventually push the disease into the more aggressive blast crisis phase, which is often fatal.

"The idea was that these indolent and aggressive leukemia cells have different ways of using nutrients such as amino acids, which regulate the balance between differentiation and cell growth," Ito said. "If we can understand what regulates that balance, we may be able to harness the pathway, to stop the disease progression or revert it back to a less aggressive disease."

By analyzing blood and leukemia cells from both the indolent chronic phase and more aggressive blast crisis phase, the research team observed higher concentrations of the BCAAs in the aggressive phase. What was unclear was whether the presence of BCAAs was a consequence or a cause leading to the more aggressive phase.

They identified one gene, BCAT1, encoding for an enzyme that can produce BCAAs in the leukemia cells.

The team used a knock-down approach to inhibit the function of the gene, to determine BCAT's importance in the aggressive phase, testing the approach in mice and human blood samples from patients with leukemia.

By blocking the BCAT1 gene, the research team was able to promote differentiation in the blast crisis cells, making the disease less aggressive and slow growing, similar to the treatable chronic phase.

Importantly, although BCAT1 is high in leukemia cells, normal blood cells show low BCAT1 levels, and normal blood cells showed little impact by the BCAT1 inhibition.

These findings suggest that BCAT1 may be an ideal therapeutic target that does little harm on normal blood production. Furthermore, results indicated that BCAT1 is also a key player in , which is more prevalent than the blast crisis . Patients with AML with high BCAT1 tend to survive less than those with low BCAT1. Blocking the BCAT1 activity also proved effective on human acute cells.

"The classical view is that no cells are known to produce BCAA by themselves—it is taken from the food we eat, always utilized as is or to be broken down inside the body," Ito said. "But leukemia cells actually take advantage of this enzyme, use the metabolic reaction in reverse to make BCAAs for their favor—for cell growth and progression to the more aggressive state."

Explore further: Brain cancer: Hunger for amino acids makes it more aggressive

More information: Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia, Nature (2017).

Related Stories

Brain cancer: Hunger for amino acids makes it more aggressive

June 24, 2013
An enzyme that facilitates the breakdown of specific amino acids makes brain cancers particularly aggressive. Scientists from the German Cancer Research Center discovered this in an attempt to find new targets for therapies ...

Combination therapy shows promise for chronic myeloid leukemia

September 7, 2016
A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment. CML ...

Protein networks help identify new chemo drug candidates

November 26, 2015
An experimental chemotherapy kills leukemia cells that are abundant in proteins critical to cancer growth, according to new research from Weill Cornell Medicine.

Body's own gene editing system generates leukemia stem cells

June 9, 2016
Cancer stem cells are like zombies—even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors. Researchers ...

New study into leukemia offers clearer understanding of its biology

January 27, 2017
Leukemia affects 350,000 people worldwide. It is a cancer of the white blood cells, which are the cells of the immune system and are produced by stem cells in the bone marrow. There are two types of chronic and two types ...

Study determines efficacy of two drugs to treat a form of leukemia

October 24, 2016
Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.

Recommended for you

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.